Introduction
It has been previously shown that the level ofcirculating undercarboxylated osteocalcin (ucOC) is elevated in elderly women in comparison with young, healthy, premenopausal ones. To understand the mechanism of the increase in the ucOC in the elderly and to assess its potential consequences on bone fragility, we have measured ucOC in the sera of 195 elderly institutionalized women 70-101 yr of age. In 45 women (23%) serum ucOC was above the upper limit of the normal range for young women. The level of ucOC was negatively correlated with 250HD (r = -0.32, P < 0.001) even after excluding the effect of age, parathyroid hormone (PTH), and creatinine by partial correlation (r = -0.24, P < 0.002). During an 18-mo followup, 15 women sustained a hip fracture and their baseline ucOC level was higher (P < 0.01) in women who subsequently sustained hip fracture than in the nonfracture group contrasting with no significant differences for serum calcium, phosphate, alkaline phosphatase, creatinine, PTH, 250HD, and total and carboxylated OC. The risk of hip fracture was increased in women with elevated ucOC (relative ratio 5.9, 99.9% Cl 1.5-22.7, P < 0.001). During 1 yr ofcalcium/vitamin D2 treatment, ucOC decreased (P < 0.05), especially in those with the initially increased values (from 2.22±0.35 to 1.41±0.29 ng/ml, P < 0.005) contrasting with an increase in the placebo group (P < 0.05). In conclusion, the increase in ucOC in the elderly reflects not only some degree of vitamin K deficiency but also their poor vitamin D status, suggesting that vitamin D may be important, either directly or indirectly through its effect on bone turnover, for achieving a normal y-carboxylation of OC. The ucOC, but not conventional calcium metabolism parameters, predicts the subsequent risk of hip fracture, suggesting that serum ucOC reflects some changes in bone matrix associated with increased fragility. Osteocalcin (OC) ' is a bone-specific protein (1) that circulates in blood. Many studies have shown over the last 10 years that the serum OC level is a sensitive marker of bone turnover that reflects specifically bone formation (2) . OC is characterized by the presence of y-carboxyglutamic acid residues (GLA). GLA residues are important for the binding ofOC to hydroxyapatite and for its presence in bone (3, 4) . The synthesis of OC depends on both the vitamin D and vitamin K. Vitamin D induces directly the OC synthesis by promoting the transcription of its gene (5) . Vitamin K stimulates the posttranslational y-carboxylation ofglutamic acid residues in the OC propeptide (1, 6) . Warfarin, a potent vitamin K antagonist, impairs the ,y-carboxylation ofOC, which is reflected by its decreased binding to the hydroxyapatite (7, 8) .
We have previously shown that the undercarboxylated fraction of circulating OC (ucOC), i.e., the fraction of OC which does not bind to hydroxyapatite, is significantly increased in elderly women, suggesting an age-dependent impairment of the y-carboxylation of OC (9) . The ucOC level was increased slightly after the menopause, but it increased markedly in women after 70 yr ofage, accounting for most ofthe increase in the circulating level of total OC in the elderly. The mechanism ofthis increase and its potential consequences on bone metabolism are not clear. Low doses of vitamin K, (1 mg/day) are able to decrease significantly serum ucOC within 2 wk (10, 11), suggesting a role of vitamin K deficiency. One of the major components of circulating vitamin K2, menaquinone-8, is decreased in the elderly ( 12) and there is growing evidence for vitamin K, and K2 deficiency in patients with hip fractures ( 1 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Conversely, there is some in vitro evidence that vitamin D might stimulate the -y-carboxylation of OC and other GLA-containing proteins ofthe kidney (16, 17) . This observation could be relevant to the age-related impairment of the carboxylation ofOC, in that vitamin D deficiency is a common feature in the elderly population (18) . The present study was designed to address the following questions: (a) Is the increase of circulating ucOC in the elderly women related to vitamin D deficiency? (b) Is the increase in ucOC correlated with an increased risk of osteoporosis, i.e., hip fracture? To answer these two questions, total, carboxylated (carbOC) and ucOC, 250HD, and other parameters of bone metabolism were measured in a large population of elderly women. The baseline measurements were correlated with the subsequent risk of hip fracture during an 18-mo follow-up. Finally, the effect ofa low dose of calcium and vitamin D on the biochemical indices was analyzed.
Methods
Materials. This study is a part ofa large prospective trial on the effect of vitamin D and calcium treatment on the incidence of hip fracture performed in more than 3,000 elderly women ( 19) . Their physical activity ranged from going outdoors to walking indoors with help. Women with serious medical conditions were excluded as well as women receiving medicines inducing osteoporosis (within the past year), vitamin D and/or calcium (for > 1 yr), sodium fluoride (for > 3 mo), and warfarin homologues (at the moment of the recruitment). Local ethical committee approval and an informed personal consent were obtained. The women were randomly assigned to groups treated daily with vitamin D2, 800 IU daily, and 1.2 g ofthe elementary calcium given as calcium phosphate, or to a double placebo. Measurements of baseline levels of OC, PTH, 250HD, alkaline phosphatase, calcium, phosphorus, and creatinine were performed in 195 patients who were followed prospectively during 18 mo. The main goal of the clinical follow-up was to record the occurrence of hip and other nonvertebral fractures ( 19) . In 139 ofthem (71 in the treated group and 68 subjects in the placebo group), the concentration of OC and its undercarboxylated fraction were also measured after 6 and 12 mo. Serum samples were stored frozen at -30'C until the time of the measurement.
The data on the intensity of the sunlight are multiyear average values for the region of Lyon measured in the Meteorogical Laboratory, Lyon-Bron (20) . The sun exposure is calculated as the total number of sunny hours per month. The fraction of sun exposure is calculated as the sun exposure divided by the sum of hours between sunrise and sunset for each day during a given month, and expressed in percent. The circannual variation of 250HD, total and ucOC, and their correlation with the sunlight exposure were evaluated in 260 patients including 195 patients of the study and 65 patients who were lost during the follow-up.
Methods. The OC level was measured with the previously described radioimmunoassay (21) using the rabbit polyclonal antiserum (AS 140) which has the same affinity for native OC and thermically decarboxylated OC. The bound OC was precipitated with the mixture of sheep anti-rabbit IgG antiserum and polyethylene glycol (PR CIS BIO Industrie, France) and centrifuged. The precipitate was rinsed with the assay buffer and recentrifuged. The sensitivity of this assay is 0.2 ng/ ml. The method of measurement of the ucOC based on different affinity of carbOC and decarboxylated OC for hydroxyapatite, is described in detail elsewhere (21 ) . Briefly, 250-ml samples were incubated with 5 and with 10 mg ofhydroxyapatite (calcium phosphate tribasic type IV, Sigma Chemical Co.) in an Eppendorf tube and mixed end-over-end for 1 h at +4°C and then centrifuged.
These two concentrations ofhydroxyapatite were chosen inasmuch as they give the best discrimination between the hydroxyapatite binding of fully carboxylated bovine OC and thermically decarboxylated bovine OC spiked into an OC-depleted human serum (21 ) . This is a valid estimate of the noncarboxylated fraction of OC, although it should not be regarded as an absolute measurement of the degree of carboxylation of OC, because a significant fraction of fully decarboxylated OC binds to hydroxyapatite (21 ) . The ucOC concentration, calculated as the mean of concentrations of duplicate measurements performed in both supernatants (with 5 and 10 mg of hydroxyapatite), represents the concentration of OC which is not bound to hydroxyapatite. The ucOC level was also expressed as the percentage of total OC concentration (ncOC%) and represents the fraction of total OC that does not bind to hydroxyapatite. The carbOC concentration was calculated as the difference between total OC and ucOC and is OC bound to hydroxyapatite. The upper limit of the normal range for OC and its fractions was calculated as the mean + 2 SD in 21 healthy, premenopausal women, aged 21-44 yr (9) . Thus, the upper limits of normal are 13.9 ng/ml for total OC, 12.5 ng/ml for carbOC, and 1.65 ng/ml ( 16.7% of total) for ucOC. The coefficients of variation (CV) for the unbound fraction of osteocalcin were the following: the intraassay CV was 6.0% for 0.38 ng/ml of ucOC, 8.8% for 1.08 mg/ml, 4.6% for 1.59 ng/ml; the interassay CV was 12.3% for 0.39 ng/ml, 5.3% for 1.13 ng/ml, and 9.1% for 1.64 ng/ml.
The serum concentrations of calcium, inorganic phosphorus, total protein, and creatinine were measured by spectrophotometry. The corrected total plasma calcium level was calculated according the formula described by Parfitt (22) . Intact 1-84 PTH concentration was measured using the Magic Lite Intact PTH Immunoassay (CIBA Corning). The 250HD level was determined with a radiobinding assay kit (Buhlmann Laboratories AG, Switzerland). The Ia,25-dihydroxyvitamin D ( Ia,25(OH)2D) level was determined using a radiocompetitive assay kit after an acetonitril extraction (Nichols Institute) in 36 women at baseline and after treatment. The alkaline phosphatase activity was measured using automated analyzer (Boehringer Mannheim GmbH, Mannheim, FRG).
Statistical analysis. Partial correlation coefficients (23) were calculated using the appropriate formulas. For the comparisons between groups and within groups the analysis of variance (ANOVA) and Student's t test (paired and unpaired) were used. The relative hip fracture risk was estimated with the exposure relative ratio (RR). The MantelHaensel method (24) of estimation was employed with strata defined by the treatment group (vitamin D plus calcium vs. placebo), presence of diseases (Parkinson's disease, previous stroke, lower limb dysfunction, transient ischemic attacks, paroxysmal arrhythmias, marked dementia, blindness) (25) and treatment with drugs known to increase the risk ofhip fracture (neuroleptics, antidepressors, long half-life anxiolytics) (26) .
Results
Baseline biochemical measurements. Baseline biochemical measurements were compared to normal values established in a group of young healthy women. Serum ucOC was increased in our group of elderly women ( 1.22±1.00 vs. 0.65±0.50 ng/ ml, P < 0.01). Based on the upper limit of normal of 1.65 ng/ml for young healthy women, 45 of the elderly women in this study, i.e., 23% had an elevated ucOC concentration. Women with a high serum ucOC level had a significantly lower 250HD level, higher serum PTH, and alkaline phosphatase activity than women with a normal ucOC (Table I) . Serum Table  II) . Similarly, ucOC expressed as the percentage of total OC correlated with 250HD level (r = -0.21, P < 0.01). In 36 women, in whom it was measured, 1 a,25 (OH)2D was not significantly correlated with total OC, ucOC, or ucOC% (r = 0.05, r = 0.16, r = 0.28, respectively). Serum 250HD revealed a circannual rhythm (F = 4.48, P < 0.001) with the highest concentrations during the summer (data not shown). An opposite circannual rhythm, with the highest levels during the winter and the lowest ones in summer, was observed for ucOC expressed in ng/ml (F = 2.23, P < 0.01, Fig. 1 A) and in percent oftotal OC (F = 4.42, P< 0.001, Fig. 1  B) . The circannual variation of total OC was borderline (F = 1.8, P < 0.06) and that of carbOC was not significant (F = 1.54,P=NS).
The average monthly 250HD level correlated both with sun exposure (r = 0.65, P < 0.03) and with the fraction of sun exposure (r = 0.67, P < 0.02). Similarly, the average monthly concentration of ucOC correlated both with sun exposure (r = -0.66, P < 0.02) and with the fraction of sun exposure (r = -0.64, P < 0.03). The average monthly ucOC% disclosed even stronger correlations both with sun exposure (r = -0.85, P < 0.001) and the fraction of sun exposure (r = -0.84, P < 0.001). Neither total OC nor carbOC correlated with sun exposure or the fraction of sun exposure.
Serum ucOC and the risk ofhipfracture. During the 18-mo follow-up ofour population, 15 patients had a hip fracture (5.1 fractures per 100 patient-years). As shown in Table III , in patients who subsequently sustained a hip fracture, serum ucOC, but no other baseline clinical and biochemical measurements, was significantly higher than in those without subsequent hip fracture. The hip fracture risk was significantly higher in women with the elevated (> 1.65 ng/ml) ucOC level with a relative risk of 5.9 (99.9% confidence interval: 1.5-22.7, P < 0.001) after adjusting for the group oftreatment (vitamin D and calcium vs. placebo), for the presence of associated diseases and for the treatment with drugs increasing the hip fracture risk (Table IV) . Similarly, the adjusted risk of hip fracture was higher in women with the elevated (> 16.7%) ucOC% with a relative risk of 3.1 (95% confidence interval: 1.8-5.9, P < 0.05). Effect oftreatment on ucOC. During the treatment period, total OC was slightly higher in the placebo group than in the group treated with calcium and vitamin D (Fig. 2) . The ucOC concentration increased in the placebo group (P < 0.05) and decreased in the treated group (P < 0.05) and mean values were significantly different at 6 and 12 mo. In the calcium/vitamin D-treated tion was found between the initial us quent decrease (r = 0.62, P < 0.001 ) patients with the initially elevated ucC vitamin D treatment decreased marke expressed in nanograms per milliliter ( age of total OC (P < 0.001 ) wherea constant in the placebo-treated subgrn tially normal ucOC level (< 1.65 r mained constant in the vitamin D-tr significantly in the placebo-treated on remained within the normal range ol pected, treatment did not chani la,25(OH)2D (from 25± 10 at baseli treatment in the calcium/vitamin D 26±9 pg/ml in the placebo group).
Discussion
In this study we have measured the c with the hydroxyapatite technique des ,dly ucOC concentration technique, based on the much higher affinity ofcarbOC than of P< 0.005) or in percentthermically decarboxylated OC for hydroxyapatite, has been as ucOC level remained validated in rats treated with warfarin, a vitamin K antagonist cup. In patients with inithat inhibits the y-carboxylation of OC and other GLA-conig/ml), ucOC level retaining proteins (3). A decreased binding of circulating OC to -eated subgroup but rose hydroxyapatite has also been documented in patients on warie (P < 0.01 ) although it farin therapy (7) (8) (9) 21 ). In elderly women with an increased f values (Fig. 3) . As exfraction of ucOC, a 2-wk treatment with low doses of vitamin ge significantly serum K induces a significant increase of the hydroxyapatite binding ne to 28±11 pg/ml after of circulating OC (10, 11) . These data indicate that the hygroup, from 29±10 to droxyapatite-based assay of ucOC is sensitive, although it provides a relative-rather than an absolute-estimate of the degree ofcarboxylation ofcirculating OC. Our measurements are based on the average of two incubations ofthe serum with two concentrations ofhydroxyapatite that provide the best discrimi--irculating level of ucOC nation between the binding of carboxylated and fully decarscribed by Price (3) . This boxylated OC (21) . With these assay conditions, a small (< 10%) offully carboxylated OC does not bind to hydroxyapatite. More importantly, a significant fraction (-50%) In this study, we have confirmed in a larger population that the circulating levels of ucOC are significantly increased as 15- compared to young healthy women (10, 11) . As previously -0.001 mentioned, vitamin K deficiency is the most likely cause ofthe subnormal carboxylation of OC (7) (8) (9) (10) (11) (12) (13) (14) (15) (27) (28) (29) . When renal function is not impaired, vitamin D deficiency leads to an increased PTH secretion which in turns stimulates I a-hydroxylation, leading to a compensatory increase of the conversion of 250HD to la,25(OH)2D. In a recent study performed in osteomalacia, we have also shown that serum OC is a marker of the level of bone turnover, assessed by histomorphometry, and does not correlate with serum la,25(OH)2D (29) . Moreover, in the elderly, low doses of vitamin D increase serum 250HD but not la,25(OH)2D3 (19, (30) (31) (32) .
The effect of calcium supplementation itself on ucOC cannot be ruled out, inasmuch as our study did not compare a vitamin D alone treatment group. The combination ofcalcium and vitamin D has been shown previously to decrease bone turnover in the elderly, by decreasing the secondary hyperparathyroidism associated with aging ( 19, 30) . This increase of bone turnover might affect-through an unidentified mechanism-the degree of carboxylation of OC. Analyzing separately the effect of calcium supplement alone and vitamin D supplementation might be useful to address this issue. Because of the correlation between ucOC and 25OHD at baseline, we believe that vitamin D supplementation is likely to play a major role in the decrease of ucOC under treatment. As stated above, this effect could be indirect mediated by changes in bone turnover, but it also rises the intriguining possibility that vitamin D has a direct effect on the y-carboxylation of OC. Karl and Friedman (16) described a stimulatory time-and dose-dependent effect of 1 a,25 (OH)2D3 on the y-carboxylase activity in the microsomes of the renal tubular cells in the rat. In the adult rat, I a,25 (OH )2D3 stimulates the y-carboxylation of the glutamic acid similarly to vitamin K ( 17) . The vitamin D-deficient diet induced a decrease in the GLA content in the femoral bone in the rat ( 17) but not in the chicken (33) . Conversely, in rats on warfarin, administration of la,25 (OH)2D3 did not increase the OC content of bone, suggesting that vitamin D cannot counteract the inhibition of y-carboxylase activity due to high doses ofwarfarin (34) . In summary, an effect of vitamin D on the microsomal gammcarboxylase activity is possible but needs to be further documented by in vitro experiments.
The most striking finding in our study was the strong correlation between serum level of ucOC and the subsequent risk of hip fracture during follow-up. The relative risk of hip fracture was six times higher in women with abnormally high value of serum ucOC. In contrast, none of the other biochemical indices had any predictive value for the risk of hip fracture. These data suggest that increased ucOC is associated with increased bone fragility, through a mechanism that remains to be elucidated. In that OC binds to bone hydroxyapatite through its GLA residues (3), undercarboxylation of OC results in a decrease ofthe bone matrix content ofGLA as shown experimentally in warfarin treated rats (4, 34) . However, the role of such a decrease on bone metabolism and bone mass is not clear, as the function ofosteocalcin is still elusive. OC is chemotactic for osteoclastic cells and could play a role in the induction ofbone resorption and bone turnover (35) (36) (37) . Chronic warfarin treatment impairs bone development in the rat (38) and has been shown recently to induce bone turnover abnormalities and osteopenia in growing lambs (39) but not in rats (4, 40) . Bone mineral density has been reported to be slightly but significantly decreased in patients on long-term warfarin therapy (41) (42) (43) .
In summary, we have found in an elderly population a significant increase of serum ucOC that is a marker of the risk of hip fracture. Serum ucOC was decreased by calcium/vitamin D treatment which has been shown in a much larger population to induce a 30% decrease of the incidence of hip fracture over 18 mo ( 19 ) . In the elderly population, especially in those living in institution, poor nutrition, lack of sunlight exposure and skin aging result in both vitamin D ( 18, 44, 45) and vitamin K deficiency (12) (13) (14) (15) . Our data suggest that ucOC is not only a marker of vitamin K deficiency but also of vitamin D deficiency, although the mechanism by which ucOC is linked to bone fragility is yet unclear. It should be stressed that our findings were obtained in a population of institutionalized women, that are vitamin D deficient and therefore not representative of the general population. The predictive value ofserum ucOC towards the risk ofhip fracture in the general aging population needs to be evaluated. 
